Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine

Headache

Volumn 47, Issue 8, 2007, Pages 1169-1177

  Chen, Li Chia ^a   Ashcroft, Darren M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acute migraine attack; Almotriptan; Meta analysis; Systematic review

Indexed keywords

ALMOTRIPTAN; PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; ASTHENIA; CHEST TIGHTNESS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MIGRAINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CONFIDENCE INTERVALS; DATABASES, BIBLIOGRAPHIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 34648822035     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00884.x     Document Type: Review

References (36)

1. The International Classification of Headache Disorders:2nd edition. Cephalalgia. 2004 24:9 160.
2. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin. 2001 17 (Suppl 1 s4-s12.
3. Lipton RB, Stewart WF, Von KM. Burden of migraine: Societal costs and therapeutic opportunities. Neurology. 1997 48:S4 S9.
4. Lipton RB, Stewart WF, Von KM. The burden of migraine. A review of cost to society. Pharmacoeconomics. 1994 6:215 221.
5. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002 59:1084 1088.
6. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001 10:1831 1845.
7. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 358:1668 1675.
8. Tfelt-Hansen P, De VP, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 60:1259 1287.
9. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 22:633 658.
10. Dahlof CGH, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache. 2002 42:99 113.
11. Dahlof C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology. 2001 57:1811 1817.
12. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: Results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia. 2002 22:453 461.
13. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000 20:588 596.
14. Pharmaceutical Research and Manufacturers of America. Clinical Study Results Database. http://www.clinicalstudyresults.org (accessed 15 December 2006).
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996 17:1 12.
16. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991 31:295 299.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 7:177 188.
18. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004 23:1351 1375.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 21:1539 1558.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003 327:557 560.
21. Diener H-C, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Eur Neurol. 2005 53:41 48.
22. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: Results of the AEGIS trial (AXERT?Early Migraine Intervention Study). Headache. 2007 47:189 198.
23. Spierings ELH, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001 58:944 950.
24. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand. 2007 115:34 40.
25. Cabarrocas X. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: A randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 23:1867 1875.
26. Dodick DW. Oral almotriptan in the treatment of migraine: Safety and tolerability. Headache. 2001 41:449 455.
27. Dahlof CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: Pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia. 2006 26:400 408.
28. Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: Results from three controlled clinical trials. Headache. 2002 42:21 27.
29. Dodick DW. Triptan nonresponder studies: Implications for clinical practice. Headache. 2005 45:156 162.
30. Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: A pooled analysis. Headache. 2002 42:S26 S31.
31. Dahlof CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans - Review of four trials. Cephalalgia. 2006 26:98 106.
32. Mathew NT. Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clin Ther. 2002 24:520 529.
33. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000 20:765 786.
34. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: Quantitative systematic review. Pain. 2002 97:247 257.
35. B/1D agonist. Cephalalgia. 1997 17:421.
36. Diener H-C, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache. 2005 45:874 882.